TRASTUZUMAB IMBOTOLIMOD
UNII LNG8RG3NMF

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Imbotolimod, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LNG8RG3NMF.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2643926-85-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LNG8RG3NMF

CAS Registry Number

2643926-85-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TRASTUZUMAB IMBOTOLIMOD

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C172388

National Cancer Institute reference terminology for clinical and research data.

INN ID

12382

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Imbotolimod. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TRASTUZUMAB IMBOTOLIMOD

Common Names & Synonyms

TRASTUZUMAB IMBOTOLIMOD [INN]

TRASTUZUMAB IMBOTOLIMOD [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2) (HUMAN-MUS MUSCULUS MONOCLONAL BDC-1001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BDC-1001 .KAPPA.-CHAIN, DIMER, N6-(33-(4-(4-AMINO-2-BUTYL-1H-IMIDAZO(4,5-C)QUINOLIN-8-YL)-1-PIPERAZINYL)-1-OXO-4,7,10,13,16,19,22,25,28,31-DECAOXATRITRIACONT-1-YL)-L-LYSINE

SYS